Targeting myocardial remodelling to develop novel therapies for heart failure: A position paper from the Working Group on Myocardial Function of the European Society of Cardiology

Guido Tarone, Jean Luc Balligand, Johann Bauersachs, Angela Clerk, Leon De Windt, Stephane Heymans, Denise Hilfiker-Kleiner, Emilio Hirsch, Guido Iaccarino, Ralph Knöll, Adelino F. Leite-Moreira, André P. Lourenço, Manuel Mayr, Thomas Thum, Carlo G. Tocchetti

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The failing heart is characterized by complex tissue remodelling involving increased cardiomyocyte death, and impairment of sarcomere function, metabolic activity, endothelial and vascular function, together with increased inflammation and interstitial fibrosis. For years, therapeutic approaches for heart failure (HF) relied on vasodilators and diuretics which relieve cardiac workload and HF symptoms. The introduction in the clinic of drugs interfering with beta-adrenergic and angiotensin signalling have ameliorated survival by interfering with the intimate mechanism of cardiac compensation. Current therapy, though, still has a limited capacity to restore muscle function fully, and the development of novel therapeutic targets is still an important medical need. Recent progress in understanding the molecular basis of myocardial dysfunction in HF is paving the way for development of new treatments capable of restoring muscle function and targeting specific pathological subsets of LV dysfunction. These include potentiating cardiomyocyte contractility, increasing cardiomyocyte survival and adaptive hypertrophy, increasing oxygen and nutrition supply by sustaining vessel formation, and reducing ventricular stiffness by favourable extracellular matrix remodelling. Here, we consider drugs such as omecamtiv mecarbil, nitroxyl donors, cyclosporin A, SERCA2a (sarcoplasmic/ endoplasmic Ca2 + ATPase 2a), neuregulin, and bromocriptine, all of which are currently in clinical trials as potential HF therapies, and discuss novel molecular targets with potential therapeutic impact that are in the pre-clinical phases of investigation. Finally, we consider conceptual changes in basic science approaches to improve their translation into successful clinical applications.

Original languageEnglish
Pages (from-to)494-508
Number of pages15
JournalEuropean Journal of Heart Failure
Volume16
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Heart Failure
Cardiac Myocytes
Neuregulins
Therapeutics
Muscles
Sarcomeres
Bromocriptine
Calcium-Transporting ATPases
Angiotensins
Workload
Vasodilator Agents
Diuretics
Pharmaceutical Preparations
Adrenergic Agents
Hypertrophy
Cyclosporine
Extracellular Matrix
Blood Vessels
Fibrosis
Clinical Trials

Keywords

  • Adaptive hypertrophy
  • Cardiac remodelling
  • Cardiomyocyte survival
  • Contractility
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Targeting myocardial remodelling to develop novel therapies for heart failure : A position paper from the Working Group on Myocardial Function of the European Society of Cardiology. / Tarone, Guido; Balligand, Jean Luc; Bauersachs, Johann; Clerk, Angela; De Windt, Leon; Heymans, Stephane; Hilfiker-Kleiner, Denise; Hirsch, Emilio; Iaccarino, Guido; Knöll, Ralph; Leite-Moreira, Adelino F.; Lourenço, André P.; Mayr, Manuel; Thum, Thomas; Tocchetti, Carlo G.

In: European Journal of Heart Failure, Vol. 16, No. 5, 2014, p. 494-508.

Research output: Contribution to journalArticle

Tarone, G, Balligand, JL, Bauersachs, J, Clerk, A, De Windt, L, Heymans, S, Hilfiker-Kleiner, D, Hirsch, E, Iaccarino, G, Knöll, R, Leite-Moreira, AF, Lourenço, AP, Mayr, M, Thum, T & Tocchetti, CG 2014, 'Targeting myocardial remodelling to develop novel therapies for heart failure: A position paper from the Working Group on Myocardial Function of the European Society of Cardiology', European Journal of Heart Failure, vol. 16, no. 5, pp. 494-508. https://doi.org/10.1002/ejhf.62
Tarone, Guido ; Balligand, Jean Luc ; Bauersachs, Johann ; Clerk, Angela ; De Windt, Leon ; Heymans, Stephane ; Hilfiker-Kleiner, Denise ; Hirsch, Emilio ; Iaccarino, Guido ; Knöll, Ralph ; Leite-Moreira, Adelino F. ; Lourenço, André P. ; Mayr, Manuel ; Thum, Thomas ; Tocchetti, Carlo G. / Targeting myocardial remodelling to develop novel therapies for heart failure : A position paper from the Working Group on Myocardial Function of the European Society of Cardiology. In: European Journal of Heart Failure. 2014 ; Vol. 16, No. 5. pp. 494-508.
@article{a3d47ac067ba4553b03c1697c033e72f,
title = "Targeting myocardial remodelling to develop novel therapies for heart failure: A position paper from the Working Group on Myocardial Function of the European Society of Cardiology",
abstract = "The failing heart is characterized by complex tissue remodelling involving increased cardiomyocyte death, and impairment of sarcomere function, metabolic activity, endothelial and vascular function, together with increased inflammation and interstitial fibrosis. For years, therapeutic approaches for heart failure (HF) relied on vasodilators and diuretics which relieve cardiac workload and HF symptoms. The introduction in the clinic of drugs interfering with beta-adrenergic and angiotensin signalling have ameliorated survival by interfering with the intimate mechanism of cardiac compensation. Current therapy, though, still has a limited capacity to restore muscle function fully, and the development of novel therapeutic targets is still an important medical need. Recent progress in understanding the molecular basis of myocardial dysfunction in HF is paving the way for development of new treatments capable of restoring muscle function and targeting specific pathological subsets of LV dysfunction. These include potentiating cardiomyocyte contractility, increasing cardiomyocyte survival and adaptive hypertrophy, increasing oxygen and nutrition supply by sustaining vessel formation, and reducing ventricular stiffness by favourable extracellular matrix remodelling. Here, we consider drugs such as omecamtiv mecarbil, nitroxyl donors, cyclosporin A, SERCA2a (sarcoplasmic/ endoplasmic Ca2 + ATPase 2a), neuregulin, and bromocriptine, all of which are currently in clinical trials as potential HF therapies, and discuss novel molecular targets with potential therapeutic impact that are in the pre-clinical phases of investigation. Finally, we consider conceptual changes in basic science approaches to improve their translation into successful clinical applications.",
keywords = "Adaptive hypertrophy, Cardiac remodelling, Cardiomyocyte survival, Contractility, Heart failure",
author = "Guido Tarone and Balligand, {Jean Luc} and Johann Bauersachs and Angela Clerk and {De Windt}, Leon and Stephane Heymans and Denise Hilfiker-Kleiner and Emilio Hirsch and Guido Iaccarino and Ralph Kn{\"o}ll and Leite-Moreira, {Adelino F.} and Louren{\cc}o, {Andr{\'e} P.} and Manuel Mayr and Thomas Thum and Tocchetti, {Carlo G.}",
year = "2014",
doi = "10.1002/ejhf.62",
language = "English",
volume = "16",
pages = "494--508",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "5",

}

TY - JOUR

T1 - Targeting myocardial remodelling to develop novel therapies for heart failure

T2 - A position paper from the Working Group on Myocardial Function of the European Society of Cardiology

AU - Tarone, Guido

AU - Balligand, Jean Luc

AU - Bauersachs, Johann

AU - Clerk, Angela

AU - De Windt, Leon

AU - Heymans, Stephane

AU - Hilfiker-Kleiner, Denise

AU - Hirsch, Emilio

AU - Iaccarino, Guido

AU - Knöll, Ralph

AU - Leite-Moreira, Adelino F.

AU - Lourenço, André P.

AU - Mayr, Manuel

AU - Thum, Thomas

AU - Tocchetti, Carlo G.

PY - 2014

Y1 - 2014

N2 - The failing heart is characterized by complex tissue remodelling involving increased cardiomyocyte death, and impairment of sarcomere function, metabolic activity, endothelial and vascular function, together with increased inflammation and interstitial fibrosis. For years, therapeutic approaches for heart failure (HF) relied on vasodilators and diuretics which relieve cardiac workload and HF symptoms. The introduction in the clinic of drugs interfering with beta-adrenergic and angiotensin signalling have ameliorated survival by interfering with the intimate mechanism of cardiac compensation. Current therapy, though, still has a limited capacity to restore muscle function fully, and the development of novel therapeutic targets is still an important medical need. Recent progress in understanding the molecular basis of myocardial dysfunction in HF is paving the way for development of new treatments capable of restoring muscle function and targeting specific pathological subsets of LV dysfunction. These include potentiating cardiomyocyte contractility, increasing cardiomyocyte survival and adaptive hypertrophy, increasing oxygen and nutrition supply by sustaining vessel formation, and reducing ventricular stiffness by favourable extracellular matrix remodelling. Here, we consider drugs such as omecamtiv mecarbil, nitroxyl donors, cyclosporin A, SERCA2a (sarcoplasmic/ endoplasmic Ca2 + ATPase 2a), neuregulin, and bromocriptine, all of which are currently in clinical trials as potential HF therapies, and discuss novel molecular targets with potential therapeutic impact that are in the pre-clinical phases of investigation. Finally, we consider conceptual changes in basic science approaches to improve their translation into successful clinical applications.

AB - The failing heart is characterized by complex tissue remodelling involving increased cardiomyocyte death, and impairment of sarcomere function, metabolic activity, endothelial and vascular function, together with increased inflammation and interstitial fibrosis. For years, therapeutic approaches for heart failure (HF) relied on vasodilators and diuretics which relieve cardiac workload and HF symptoms. The introduction in the clinic of drugs interfering with beta-adrenergic and angiotensin signalling have ameliorated survival by interfering with the intimate mechanism of cardiac compensation. Current therapy, though, still has a limited capacity to restore muscle function fully, and the development of novel therapeutic targets is still an important medical need. Recent progress in understanding the molecular basis of myocardial dysfunction in HF is paving the way for development of new treatments capable of restoring muscle function and targeting specific pathological subsets of LV dysfunction. These include potentiating cardiomyocyte contractility, increasing cardiomyocyte survival and adaptive hypertrophy, increasing oxygen and nutrition supply by sustaining vessel formation, and reducing ventricular stiffness by favourable extracellular matrix remodelling. Here, we consider drugs such as omecamtiv mecarbil, nitroxyl donors, cyclosporin A, SERCA2a (sarcoplasmic/ endoplasmic Ca2 + ATPase 2a), neuregulin, and bromocriptine, all of which are currently in clinical trials as potential HF therapies, and discuss novel molecular targets with potential therapeutic impact that are in the pre-clinical phases of investigation. Finally, we consider conceptual changes in basic science approaches to improve their translation into successful clinical applications.

KW - Adaptive hypertrophy

KW - Cardiac remodelling

KW - Cardiomyocyte survival

KW - Contractility

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=84899490402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899490402&partnerID=8YFLogxK

U2 - 10.1002/ejhf.62

DO - 10.1002/ejhf.62

M3 - Article

C2 - 24639064

AN - SCOPUS:84899490402

VL - 16

SP - 494

EP - 508

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 5

ER -